I heard the statistician say, “The drug does not have sufficient activity to study further in this population.” It was my co-investigator on GOG study 229C, Gefitinib in the Treatment of Advanced and Recurrent Endometrial Cancer (see related extended abstract in this issue*), calling from Roswell Park in Buffalo. He had just completed the analysis of data from 26 women treated on our study – a study which had been five years in the making from concept to clinical trial.
Clinical trials, gefitinib
Copyright © Kimberly K. Leslie, 2013.
Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.